CN104083730A - Medicine for preventing and treating mixed infection of pigs, as well as preparation method and application thereof - Google Patents
Medicine for preventing and treating mixed infection of pigs, as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN104083730A CN104083730A CN201410374471.9A CN201410374471A CN104083730A CN 104083730 A CN104083730 A CN 104083730A CN 201410374471 A CN201410374471 A CN 201410374471A CN 104083730 A CN104083730 A CN 104083730A
- Authority
- CN
- China
- Prior art keywords
- medicine
- mixed infection
- pig
- extract
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 58
- 208000003322 Coinfection Diseases 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 241000282887 Suidae Species 0.000 title abstract description 6
- 229940079593 drug Drugs 0.000 title description 14
- 239000000284 extract Substances 0.000 claims abstract description 44
- JTSDBFGMPLKDCD-XVFHVFLVSA-N tilmicosin Chemical compound O([C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CCN1C[C@H](C)C[C@H](C)C1)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@@H]1O[C@H](C)[C@@H](O)[C@H](N(C)C)[C@H]1O JTSDBFGMPLKDCD-XVFHVFLVSA-N 0.000 claims abstract description 20
- 229960000223 tilmicosin Drugs 0.000 claims abstract description 20
- 239000002994 raw material Substances 0.000 claims abstract description 14
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 13
- 239000009188 angelicae sinensis extract Substances 0.000 claims description 13
- 239000002671 adjuvant Substances 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 229960001031 glucose Drugs 0.000 claims description 9
- 240000008042 Zea mays Species 0.000 claims description 6
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 claims description 6
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 6
- 235000010358 acesulfame potassium Nutrition 0.000 claims description 6
- 235000009973 maize Nutrition 0.000 claims description 6
- 235000012054 meals Nutrition 0.000 claims description 6
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- 229960004998 acesulfame potassium Drugs 0.000 claims description 5
- 239000000619 acesulfame-K Substances 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- 239000004384 Neotame Substances 0.000 claims description 4
- 235000007164 Oryza sativa Nutrition 0.000 claims description 4
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 claims description 4
- 235000010357 aspartame Nutrition 0.000 claims description 4
- 230000009286 beneficial effect Effects 0.000 claims description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 4
- 229960001375 lactose Drugs 0.000 claims description 4
- 235000019412 neotame Nutrition 0.000 claims description 4
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 claims description 4
- 108010070257 neotame Proteins 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 235000009566 rice Nutrition 0.000 claims description 4
- 229940085605 saccharin sodium Drugs 0.000 claims description 4
- 229960004793 sucrose Drugs 0.000 claims description 4
- 108010011485 Aspartame Proteins 0.000 claims description 3
- 239000000605 aspartame Substances 0.000 claims description 3
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 3
- 229960003438 aspartame Drugs 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 229940088417 precipitated calcium carbonate Drugs 0.000 claims description 3
- 239000004376 Sucralose Substances 0.000 claims description 2
- 229940109275 cyclamate Drugs 0.000 claims description 2
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 claims description 2
- 235000019408 sucralose Nutrition 0.000 claims description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 2
- 240000007594 Oryza sativa Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 13
- 241000204031 Mycoplasma Species 0.000 abstract description 9
- 241001465754 Metazoa Species 0.000 abstract description 8
- 241000700605 Viruses Species 0.000 abstract description 5
- 235000013305 food Nutrition 0.000 abstract description 4
- 241000894006 Bacteria Species 0.000 abstract description 3
- 239000003640 drug residue Substances 0.000 abstract description 3
- 238000000034 method Methods 0.000 abstract description 3
- 239000000273 veterinary drug Substances 0.000 abstract description 3
- 229940088710 antibiotic agent Drugs 0.000 abstract description 2
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 235000014375 Curcuma Nutrition 0.000 abstract 1
- 244000164480 Curcuma aromatica Species 0.000 abstract 1
- 240000009138 Curcuma zedoaria Species 0.000 abstract 1
- 235000003405 Curcuma zedoaria Nutrition 0.000 abstract 1
- 241000951473 Schizonepeta Species 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 abstract 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 abstract 1
- 238000009313 farming Methods 0.000 abstract 1
- 235000003599 food sweetener Nutrition 0.000 abstract 1
- 239000003765 sweetening agent Substances 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 235000019509 white turmeric Nutrition 0.000 abstract 1
- 241000282898 Sus scrofa Species 0.000 description 77
- 238000011282 treatment Methods 0.000 description 16
- 230000000844 anti-bacterial effect Effects 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 238000002651 drug therapy Methods 0.000 description 5
- 210000001015 abdomen Anatomy 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 235000010216 calcium carbonate Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- -1 fter Species 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 241000209094 Oryza Species 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 230000000994 depressogenic effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 208000012153 swine disease Diseases 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- ZVMJXSJCBLRAPD-UHFFFAOYSA-N Epicurzerenone Natural products C1C(C=C)(C)C(C(=C)C)C(=O)C2=C1OC=C2C ZVMJXSJCBLRAPD-UHFFFAOYSA-N 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- DEBDFZGNZTYPMF-NZBPQXDJSA-N Isocurcumenol Chemical compound C=C1C[C@](O2)(O)C(=C(C)C)C[C@@]22[C@@H](C)CC[C@H]21 DEBDFZGNZTYPMF-NZBPQXDJSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- RHBOHEXDGUVIIY-WHOFXGATSA-N Procurcumenol Chemical compound CC1=CC(=O)C(=C(C)C)C[C@@H]2[C@](O)(C)CC[C@H]21 RHBOHEXDGUVIIY-WHOFXGATSA-N 0.000 description 2
- 208000036071 Rhinorrhea Diseases 0.000 description 2
- 206010039101 Rhinorrhoea Diseases 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 238000009402 cross-breeding Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000003255 drug test Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001047 pyretic effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 1
- NFLGAXVYCFJBMK-DTWKUNHWSA-N (+)-menthone Chemical group CC(C)[C@H]1CC[C@H](C)CC1=O NFLGAXVYCFJBMK-DTWKUNHWSA-N 0.000 description 1
- HICAMHOOTMOHPA-HIFRSBDPSA-N (5r,6r)-6-ethenyl-3,6-dimethyl-5-prop-1-en-2-yl-5,7-dihydro-4h-1-benzofuran Chemical compound C1[C@@](C=C)(C)[C@@H](C(=C)C)CC2=C1OC=C2C HICAMHOOTMOHPA-HIFRSBDPSA-N 0.000 description 1
- ZVMJXSJCBLRAPD-DZGCQCFKSA-N (5r,6s)-6-ethenyl-3,6-dimethyl-5-prop-1-en-2-yl-5,7-dihydro-1-benzofuran-4-one Chemical compound C1[C@](C=C)(C)[C@@H](C(=C)C)C(=O)C2=C1OC=C2C ZVMJXSJCBLRAPD-DZGCQCFKSA-N 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000195622 Astasia Species 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- QRMPRVXWPCLVNI-UHFFFAOYSA-N Curcumenol Natural products C1C(=C)C2CCC(C)C22CC(C(C)C)C1(O)O2 QRMPRVXWPCLVNI-UHFFFAOYSA-N 0.000 description 1
- ZVMJXSJCBLRAPD-ZFWWWQNUSA-N Curzerenone Chemical compound C1[C@@](C=C)(C)[C@@H](C(=C)C)C(=O)C2=C1OC=C2C ZVMJXSJCBLRAPD-ZFWWWQNUSA-N 0.000 description 1
- 206010051244 Dyschezia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- RHBOHEXDGUVIIY-UHFFFAOYSA-N Epiprocurcumenol Natural products CC1=CC(=O)C(=C(C)C)CC2C(O)(C)CCC21 RHBOHEXDGUVIIY-UHFFFAOYSA-N 0.000 description 1
- KBEBGUQPQBELIU-CMDGGOBGSA-N Ethyl cinnamate Chemical compound CCOC(=O)\C=C\C1=CC=CC=C1 KBEBGUQPQBELIU-CMDGGOBGSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010052140 Eye pruritus Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 206010021079 Hypopnoea Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- HICAMHOOTMOHPA-UHFFFAOYSA-N Isofuranogermacren Natural products C1C(C=C)(C)C(C(=C)C)CC2=C1OC=C2C HICAMHOOTMOHPA-UHFFFAOYSA-N 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- GTUFHYHOPUHIKF-UHFFFAOYSA-N Schizonodiol Natural products CC1CC(=O)C(C(C)(C)O)=CC1O GTUFHYHOPUHIKF-UHFFFAOYSA-N 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- KBEBGUQPQBELIU-UHFFFAOYSA-N cinnamic acid ethyl ester Natural products CCOC(=O)C=CC1=CC=CC=C1 KBEBGUQPQBELIU-UHFFFAOYSA-N 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- ISFMXVMWEWLJGJ-NZBPQXDJSA-N curcumenol Chemical group CC1=C[C@](O2)(O)C(=C(C)C)C[C@@]22[C@@H](C)CC[C@H]21 ISFMXVMWEWLJGJ-NZBPQXDJSA-N 0.000 description 1
- QUQIBYMETMROHZ-UHFFFAOYSA-N curzerenone Natural products CCC1(C)Cc2occ(C)c2C(=O)C1C(C)C QUQIBYMETMROHZ-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229930007503 menthone Natural products 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the field of veterinary drugs, and particularly relates to a medicine for preventing and treating mixed infection of pigs, as well as a preparation method and application thereof. The medicine for preventing and treating mixed infection of pigs comprises the following raw materials in percentage by weight: 20-30 percent of curcuma zedoary extract, 10-20 percent of Chinese angelica extract, 10-20 percent of schizonepeta extract, 25-35 percent of tilmicosin, 5-15 percent of sweetening agent and the balance of auxiliaries. The medicine is simple in preparation, scientific in compatibility, simple and easily available in raw materials, low in cost, as well as economical and practical, can be directly added into pig feeds, is convenient to use, does not have toxic or side effects, has the effect of preventing and treating bacteria, virus and mycoplasma mixed infection of pigs, is a medicine which is in accordance with safe veterinary drugs and guarantees animal-derived food safety for preventing and treating mixed infection of pigs, and can effectively reduce use of antibiotics in pig farming process so as to reduce drug residues in a pig body.
Description
(1) technical field
The invention belongs to field of veterinary, particularly a kind of medicine of preventing and treating pig mixed infection and its preparation method and application.
(2) background technology
The large-scale cultivation of pig has become the trend of contemporary pig industry.Under large-scale cultivation pattern, swinery density is large, and stressors increases, and is easy to cause that pig morbidity is even dead, and wherein the mixed infection of the antibacterial of pig, virus, mycoplasma has become one of general and serious disease in pig farm.The antibacterial of pig, virus, mycoplasma mixed infection all have generation in China each province, particularly occurred frequently at pig cultivation close quarters.Pig mixed infection, without obvious seasonality, all can occur throughout the year.The constitutional factor of pig mixed infection is some Swine viruses, and after viral infection pig, pig immunity declines, and easily by mycoplasma and antibacterial, is encroached on, and causes secondary infection, and mostly the cause of death is the bacteremia that antibacterial secondary infection causes.Pig mixed infection treatment difficulty is large, and mortality rate is high, and the resistance to many undergrowths of pig of crossing, become cad pig, to raiser, have brought great economic loss.
China Ministry of Agriculture forbids that antiviral Western medicine applies in pig cultivation field.At present, the primary treatment scheme of reply pig mixed infection is for promoting the astragalus polysaccharides of pig immunity and the cephalosporins compatibility for the treatment of bacterial disease.This scheme therapeutic effect feeds back and differs throughout the country, and easily recurrence after curing.The treatment field of pig mixed infection is at present the exploratory stage in the initial stage also, more to study bacterial disease and mycoplasma disease how to control pig, also seldom have the treatment research that relates to porcine viral diseases, this has caused very large technology barrier to the rehabilitation after pig mixed infection.
(3) summary of the invention
The present invention is in order to make up the deficiencies in the prior art, provide a kind of prepare simple, compatibility science, cost low, can directly be added in pig feed, easy to use, instant effect, can reduce antibacterials in pig breeding process use, reduce medicine of the residual control pig mixed infection of pig drug disposition and its preparation method and application.
The present invention is achieved through the following technical solutions:
Prevent and treat a medicine for pig mixed infection, by the raw material of following percentage by weight, formed: Rhizoma Curcumae extract 20-30%, Radix Angelicae Sinensis extract 10-20%, Herba Schizonepetae extract 10-20%, tilmicosin 25-35%, sweeting agent 5-15%, surplus is adjuvant.
The medicine of this control pig mixed infection, the percentage by weight of its preferred each raw material is: Rhizoma Curcumae extract 25%, Radix Angelicae Sinensis extract 15%, Herba Schizonepetae extract 15%, tilmicosin 30%, sweeting agent 10% and adjuvant 5%.
Described sweeting agent is a kind of in glucide, saccharin sodium, neotame, cyclamate, aspartame, acesulfame potassium or sucralose.
Described adjuvant is any one and precipitated calcium carbonate, ground calcium carbonate, powdered rice hulls in oral glucose, anhydrous glucose, sucrose or lactose, add any one the combination in beneficial powder or maize cob meal.
The preparation method of the medicine of this control pig mixed infection, comprises the steps:
By above-mentioned percentage by weight, take Rhizoma Curcumae extract, Radix Angelicae Sinensis extract, Herba Schizonepetae extract, tilmicosin, sweeting agent and adjuvant and pulverize respectively the rear 80-100 of mistake mesh sieve, then by Rhizoma Curcumae extract, Radix Angelicae Sinensis extract, Herba Schizonepetae extract, tilmicosin, sweeting agent and adjuvant mix homogeneously, obtain the medicine of this control pig mixed infection.
The application of the medicine that the present invention prevents and treats pig mixed infection in the mixed infection of control pig.
Usage and dosage: the ratio in every 1000 kilogram of feed with 1000 grams of medicines of the present invention, medicine of the present invention is mixed in pig feed, after fully mixing, for pig free choice feeding, be used in conjunction 6-7 days.
The pharmaceutical characteristic of each raw material of the present invention is as follows:
Rhizoma Curcumae extract: Rhizoma Curcumae bitter in the mouth, pungent, temperature, returns liver, spleen channel, circulation of qi promoting removing blood stasis, removing food stagnancy pain relieving, cures mainly QI and blood pained, eating accumulation, abdominal distention ， mass in the abdomen mass in the abdomen, traumatic injury.Modern study shows, the main pharmacological component of Rhizoma Curcumae extract is curcumenol, methoxyl group ethyl cinnamate, epicurzerenone, curzerene, pyrocurcuzerenone, isocurcumenol, procurcumenol, deoxidation curzerenone etc., after oral, there is antiviral, antibacterial, antineoplastic action, can also make blood flow volume increase, quantity of leucocyte in animal body raise, there is the effect that regulates animal body immunologic function;
Radix Angelicae Sinensis extract: Radix Angelicae Sinensis sweet in the mouth, temperature, return liver, the heart, spleen channel, enrich blood and invigorate blood circulation, moisturize laxation.Cure mainly all Zheng ， of blood deficiency mass in the abdomen knot poly-, asthenia cold abdominalgia, flaccidity syndrome and arthralgia syndrome, numbness of the skin, dryness of the intestine dyschezia, heavy after bloody dysentery, ulcer sores, injury from falling down.Modern study shows: Radix Angelicae Sinensis extract has the function that promotes body hemopoietic function, anticoagulant and antithrombotic, blood fat reducing, and blood and hemopoietic function are had to the effect regulating for the treatment of; Also having enriches blood invigorates blood circulation, regulates the effect of body's immunity and anti-hypoxia;
Herba Schizonepetae extract: Herba Schizonepetae acrid in the mouth, tepor, return lung, Liver Channel, dispel the wind, induce sweat, rash, hemostasis.Cure mainly cold, fever, headache, eye itching, cough, laryngopharynx swelling and pain, measles, rubella, carbuncle, skin ulcer scabies, epistaxis, spits blood, and has blood in stool.Modern study shows: the main pharmacological component of Herba Schizonepetae extract is D-menthone, racemization menthone, nepetol, schizonodiol etc., there is antiinflammatory, antipyretic, analgesic activity, and have stronger antibacterial action, respiratory system, central nervous system are had to adjusting immunity function;
Tilmicosin: tilmicosin has powerful killing action to mycoplasma, gram positive bacteria and part gram negative bacteria, effective especially to Mycoplasma, tilmicosin main metabolites in animal body has antibacterial activity equally, and effect rapidly, metabolite drug level peak occurs after following the concentration peak of medicine of the present invention closely, and circulation time in vivo will be longer than tilmicosin, not only additionally increased antimicrobial effect, also extend the time of pathogen and medicament contact, be conducive to the treatment of disease; Tilmicosin is oral can extensively be gathered rapidly after entering in animal body in leukocyte, and infiltrates to subcellular organelle, carries the leukocyte of tilmicosin and can initiatively find and near infected animal infection site, more be conducive to the treatment of systemic infection.
The present invention prevents and treats the medicine of pig mixed infection and prepares simple, compatibility science, raw material is simple and easy to get, cost is low, economic and practical, multi-medicament is suitably coordinated, utilize its mutual collaborative or resistant function, improve curative effect, to adapt to the treatment requirement of the complicated state of an illness, reduce untoward reaction, evident in efficacy lasting, absorb fast, prove effective rapidly, can increase blood flow volume in pig body, the quantity of leukocyte increasing, and there is antiinflammatory, antipyretic, analgesia, regulate the effect of pig body immunologic function, carrying the leukocyte of tilmicosin can initiatively find and close infected animal infection site, more be conducive to the treatment of systemic infection, and to mycoplasma, gram positive bacteria and part gram negative bacteria have powerful killing action, increased antimicrobial effect, also extended the time of pathogen and medicament contact, be applicable to the needs of pig mixed infection control, in adjuvant, be added with oral glucose, anhydrous glucose, sucrose or lactose, can improve mouthfeel and the palatability of medicine, in raw material, be added with sweeting agent, can improve the bitterness of tilmicosin, avoid having influence on searching for food of pig, the medicine that the present invention prevents and treats pig mixed infection can directly be added in pig feed, easy to use, have no side effect and drug residue, there is prevention and treatment pig antibacterial, virus, the effect of mycoplasma mixed infection, it is a kind of safe veterinary drug that meets, ensure the medicine of the control pig mixed infection of animal-derived food safety, can effectively reduce antibiotic use in pig breeding process and then reduce the drug residue in pig body.
(4) specific embodiment
Below in conjunction with embodiment, the invention will be further described, but the present invention is not limited thereto, and the preparation method in embodiment is conventional preparation method, no longer describes in detail.
Embodiment 1:(weight is in double centner, as follows)
The medicine of this control pig mixed infection, is comprised of the raw material of following weight: 3 kilograms of 25 kilograms of Rhizoma Curcumae extracts, 15 kilograms of Radix Angelicae Sinensis extracts, 15 kilograms of Herba Schizonepetae extracts, 30 kilograms of tilmicosins, 10 kilograms of acesulfame potassiums, 2 kilograms of anhydrous glucose and maize cob meals;
The preparation method of the medicine of this control pig mixed infection, adopts following steps:
By above-mentioned weight, take Rhizoma Curcumae extract, Radix Angelicae Sinensis extract, Herba Schizonepetae extract, tilmicosin, acesulfame potassium, anhydrous glucose and maize cob meal and pulverize respectively the rear 80-100 of mistake mesh sieve, then by Rhizoma Curcumae extract, Radix Angelicae Sinensis extract, Herba Schizonepetae extract, tilmicosin, acesulfame potassium, anhydrous glucose and maize cob meal mix homogeneously, obtain the medicine of this control pig mixed infection.
Usage and dosage: the ratio in every 1000 kilogram of feed with 1000 grams of medicines of the present invention, medicine of the present invention is mixed in pig feed, after fully mixing, for pig free choice feeding, be used in conjunction 6-7 days.
Embodiment 2:
The medicine of this control pig mixed infection, is comprised of the raw material of following weight:
20 kilograms of Rhizoma Curcumae extracts, 10 kilograms of Radix Angelicae Sinensis extracts, 20 kilograms of Herba Schizonepetae extracts, 35 kilograms of tilmicosins, 5 kilograms of aspartames, 6 kilograms of lactose and add 4 kilograms, beneficial powder.
Preparation method and usage and dosage are with embodiment 1.
Embodiment 3:
The medicine of this control pig mixed infection, is comprised of the raw material of following weight:
4 kilograms of 30 kilograms of Rhizoma Curcumae extracts, 20 kilograms of Radix Angelicae Sinensis extracts, 10 kilograms of Herba Schizonepetae extracts, 25 kilograms of tilmicosins, 7 kilograms of neotame, 4 kilograms of sucrose and ground calcium carbonate.
Preparation method and usage and dosage are with embodiment 1.
Embodiment 4:
The medicine of this control pig mixed infection, is comprised of the raw material of following weight:
1 kilogram of 27 kilograms of Rhizoma Curcumae extracts, 12 kilograms of Radix Angelicae Sinensis extracts, 17 kilograms of Herba Schizonepetae extracts, 27 kilograms of tilmicosins, 15 kilograms of saccharin sodium, 1 kilogram of oral glucose and powdered rice hulls.
Preparation method and usage and dosage are with embodiment 1.
Embodiment 5:
The medicine of this control pig mixed infection, is comprised of the raw material of following weight:
2 kilograms of 22 kilograms of Rhizoma Curcumae extracts, 18 kilograms of Radix Angelicae Sinensis extracts, 13 kilograms of Herba Schizonepetae extracts, 32 kilograms of tilmicosins, 12 kilograms, glucide, 1 kilogram of anhydrous glucose and precipitated calcium carbonates.
Preparation method and usage and dosage are with embodiment 1.
Rhizoma Curcumae extract used, Radix Angelicae Sinensis extract, Herba Schizonepetae extract, tilmicosin, glucide, saccharin sodium, neotame, aspartame, acesulfame potassium, oral glucose, anhydrous glucose, sucrose, lactose, precipitated calcium carbonate, ground calcium carbonate, powdered rice hulls in embodiment 1-5, add beneficial powder, maize cob meal is commercially available prod.
In order to verify the clinical treatment curative effect of medicine of the present invention to pig mixed infection, the inventor adopts of the present invention medicine to ill pig to carry out therapeutic test in different pig plants to the pig of mixed infection morbidity in year May in June, 2013 to 2014, specific as follows:
Treatment example 1:
, there are 570 of DLY tri-crossbreedings on pig farm, Jinan City, Shandong Province, occurs the symptoms such as cough, rhinorrhea, spirit are depressed, fervescence in the child care stage, through clinical diagnosis, is mixed infection.
The medicine that adopts the mixed infection of the made control of the embodiment of the present invention 1 pig, the ratio in every 1000 kilogram of feed with 1000 grams of medicines of the present invention, mixes medicine of the present invention in pig feed, after fully mixing, for pig free choice feeding, is used in conjunction 7 days.
After 3 days, most of pig situation takes a turn for the better, and continues medication after 4 days, and swinery each side recovering state is normal.
Treatment example 2:
, there are 310 of DLY tri-crossbreedings on certain pig farm, Dongying city, and in the child care stage, occur cough, shed tears, the symptom such as rhinorrhea, spiritual depressed, fervescence, through clinical diagnosis, be viral mixed infection.
The medicine that adopts the mixed infection of the made control of the embodiment of the present invention 5 pig, the ratio in every 1000 kilogram of feed with 1000 grams of medicines of the present invention, mixes medicine of the present invention in pig feed, after fully mixing, for pig free choice feeding, is used in conjunction 6 days.
After 3 days, most of pig situation takes a turn for the better, and continues medication after 3 days, and swinery each side recovering state is normal.
Treatment example 3:
(1) subjects:
402 65 age in days nursery pig that raise on pig farm, Qingdao of Shandong province occur that spirit is depressed successively, congested significantly phenomenon under micro-swollen, the eye conjunctiva flushing of eyelid, intranasal secretions increase, skin rubefaction, have sharp ears, abdomen, body temperature is up to 42 ℃, indivedual pig astasias, do not play hypopnea sleepingly.Cut open inspection and see subcutaneous hyperemia, lymph nodes of body as a whole swelling, hyperemia, hemorrhage, pericardium is long-pending has a little weak yellow liquid, the broadening of lungs interstitial, lungs obviously to expand 3-4 doubly, and consolidation, is inside full of mucus, and there is cellulose sample exudate on lungs surface, and there is obvious purulent hydrops in joint.According to epidemiology, clinical symptoms and pathological anatomical change, be diagnosed as reproductive and respiratory syndrome and streptococcus mixed infection.
(2) test method:
400 pigs of the remaining mixed infection morbidity in this pig farm are divided into 4 groups at random, 100 every group, are labeled as respectively matched group, test group 1, test group 2 and test group 3.Matched group adopts clear, the round blue pentapeptide by specification drug treatment of blue circle pyretic toxicity, and test group 1 adopts the embodiment of the present invention 1 Drug therapy, and test group 2 adopts the embodiment of the present invention 2 Drug therapys, and test group 3 adopts the embodiment of the present invention 3 Drug therapys.
The usage of test group 1-test group 3 and consumption are: the ratio in every 1000 kilogram of feed with 1000 grams of medicines of the present invention, medicine of the present invention is mixed in pig feed, and after fully mixing, for pig free choice feeding, be used in conjunction 6 days.
(3) curative effect determinate standard:
Cure: within medication 5-6 days, future trouble swine diseases symptom disappears completely, spirit, body temperature, appetite recover normal, no longer occur the clinical symptoms such as fervescence, dyspnea, and urine and feces are also normal;
Effective: within medication 5-6 days, future trouble swine diseases symptom disappears substantially, and spirit, body temperature, appetite are recovered to some extent, no longer occur the clinical symptoms such as fervescence, dyspnea, and it is normal that urine and feces also recover;
Invalid: within medication 5-6 days, future trouble swine diseases symptom does not disappear.
(4) result of the test:
Table 1 clinical application therapeutic effect observed result (statistical result of the 6th day)
| Group | Cure rate (%) | Effective percentage (%) | Total effective rate (%) | Inefficiency (%) |
| Matched group | 77.3 | 15.1 | 92.4 | 7.6 |
| Test group 1 | 92.1 | 6.8 | 98.9 | 1.1 |
| Test group 2 | 89.5 | 9.2 | 98.7 | 1.3 |
| Test group 3 | 90.2 | 8.6 | 98.8 | 1.2 |
As can be seen from Table 1, the total effective rate of the ill pig of the test group 1-3 of employing Drug therapy of the present invention, all apparently higher than the matched group that adopts clear, the round blue pentapeptide treatment of blue circle pyretic toxicity, illustrates the more remarkable effect of Drug therapy pig of the present invention mixed infection.
Claims (6)
1. a medicine of preventing and treating pig mixed infection, it is characterized in that: the raw material by following percentage by weight forms: Rhizoma Curcumae extract 20-30%, Radix Angelicae Sinensis extract 10-20%, Herba Schizonepetae extract 10-20%, tilmicosin 25-35%, sweeting agent 5-15%, surplus is adjuvant.
2. a kind of medicine of preventing and treating pig mixed infection according to claim 1, is characterized in that: the raw material by following percentage by weight forms: Rhizoma Curcumae extract 25%, Radix Angelicae Sinensis extract 15%, Herba Schizonepetae extract 15%, tilmicosin 30%, sweeting agent 10% and adjuvant 5%.
3. a kind of medicine of preventing and treating pig mixed infection according to claim 1 and 2, is characterized in that: described sweeting agent is a kind of in glucide, saccharin sodium, neotame, cyclamate, aspartame, acesulfame potassium or sucralose.
4. a kind of medicine of preventing and treating pig mixed infection according to claim 1 and 2, is characterized in that: described adjuvant is any one and precipitated calcium carbonate, ground calcium carbonate, powdered rice hulls in oral glucose, anhydrous glucose, sucrose or lactose, add any one the combination in beneficial powder or maize cob meal.
5. a preparation method for the medicine of control pig as claimed in claim 1 mixed infection, is characterized in that: comprise the steps:
By above-mentioned percentage by weight, take Rhizoma Curcumae extract, Radix Angelicae Sinensis extract, Herba Schizonepetae extract, tilmicosin, sweeting agent and adjuvant and pulverize respectively the rear 80-100 of mistake mesh sieve, then by Rhizoma Curcumae extract, Radix Angelicae Sinensis extract, Herba Schizonepetae extract, tilmicosin, sweeting agent and adjuvant mix homogeneously, obtain the medicine of this control pig mixed infection.
6. the application of the medicine of a control pig as claimed in claim 1 mixed infection in the mixed infection of control pig.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410374471.9A CN104083730A (en) | 2014-07-31 | 2014-07-31 | Medicine for preventing and treating mixed infection of pigs, as well as preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410374471.9A CN104083730A (en) | 2014-07-31 | 2014-07-31 | Medicine for preventing and treating mixed infection of pigs, as well as preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104083730A true CN104083730A (en) | 2014-10-08 |
Family
ID=51631555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410374471.9A Pending CN104083730A (en) | 2014-07-31 | 2014-07-31 | Medicine for preventing and treating mixed infection of pigs, as well as preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104083730A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104523886A (en) * | 2014-12-25 | 2015-04-22 | 北京资源亚太饲料科技有限公司 | Pharmaceutical composition for preventing and treating porcine respiratory diseases as well as preparation method and application of pharmaceutical composition |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101062171A (en) * | 2007-05-18 | 2007-10-31 | 湛江市第一兽药厂 | Method for producing bacterial virus element medicine for preventing bacterial virus mixed infection for critter, fowl and aquatic animals |
| US20080152729A1 (en) * | 2006-12-21 | 2008-06-26 | Kubata Bruno K | Artemisinins in the clinical and veterinary management of kinetoplastid infections |
| CN101428125A (en) * | 2008-12-19 | 2009-05-13 | 成都青山利康药业有限公司 | Medicament composition with antiviral efficacy |
| CN103272068A (en) * | 2013-05-20 | 2013-09-04 | 广东大华农动物保健品股份有限公司 | Chinese and western medicine compound preparation containing tilmicosin and preparation method thereof |
-
2014
- 2014-07-31 CN CN201410374471.9A patent/CN104083730A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080152729A1 (en) * | 2006-12-21 | 2008-06-26 | Kubata Bruno K | Artemisinins in the clinical and veterinary management of kinetoplastid infections |
| CN101062171A (en) * | 2007-05-18 | 2007-10-31 | 湛江市第一兽药厂 | Method for producing bacterial virus element medicine for preventing bacterial virus mixed infection for critter, fowl and aquatic animals |
| CN101428125A (en) * | 2008-12-19 | 2009-05-13 | 成都青山利康药业有限公司 | Medicament composition with antiviral efficacy |
| CN103272068A (en) * | 2013-05-20 | 2013-09-04 | 广东大华农动物保健品股份有限公司 | Chinese and western medicine compound preparation containing tilmicosin and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 李美娣等: "联合应用替米考星与中药对解除免疫抑制及净化猪场蓝耳病的作用", 《养猪》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104523886A (en) * | 2014-12-25 | 2015-04-22 | 北京资源亚太饲料科技有限公司 | Pharmaceutical composition for preventing and treating porcine respiratory diseases as well as preparation method and application of pharmaceutical composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104258047A (en) | Traditional Chinese medicine composition for preventing and treating porcine reproductive and respiratory syndrome | |
| CN104257794B (en) | Chinese medicine composition of a kind of spleen reinforcing removing food stagnancy and preparation method thereof | |
| CN103141704B (en) | Traditional Chinese medicine feed for treating swine plague | |
| CN103054999B (en) | Traditional Chinese medicine preparation for preventing and treating highly pathogenic porcine reproductive and respiratory syndrome and preparation method | |
| CN102600457A (en) | Compound propolis composition used for treating pig viral diarrhea and preparation method thereof | |
| CN104083729A (en) | Medicine for preventing and treating mixed infection of fur-bearing animals as well as preparation method and application of medicine | |
| CN103768351A (en) | Traditional Chinese medicine composition for treating necrotic enteritis and preparation method thereof | |
| CN102698158A (en) | Traditional Chinese medicine for preventing and treating infectious bronchitis, preparation method thereof and feed | |
| CN104083730A (en) | Medicine for preventing and treating mixed infection of pigs, as well as preparation method and application thereof | |
| CN105381300A (en) | Traditional Chinese medicinal preparation for preventing and treating swine fever | |
| CN102379920B (en) | Veterinary antiviral and antifebrile drug composition | |
| CN102379939B (en) | Drug composition for preventing and treating exogenous fever of livestock and poultry | |
| CN104434950B (en) | A kind of Cortex Eucommiae targeting preparation for the treatment of colon cancer and preparation method thereof | |
| CN109432287B (en) | Traditional Chinese medicine oral liquid for preventing and treating excessive heat syndrome of poultry qi system and preparation method thereof | |
| CN104083731A (en) | Medicament for preventing and treating mixed infection of domestic rabbits as well as preparation method and application thereof | |
| CN101380368A (en) | Traditional Chinese medicine composition for treating birds enteritis and dysentery | |
| CN104096185A (en) | Medicine for preventing and curing mixed infection among poultry, as well as preparation method and application of medicine | |
| CN104096186A (en) | Medicine for preventing and curing mixed infection of sheep, as well as preparation method and application of medicine | |
| CN116370574B (en) | Traditional Chinese medicine composition for preventing and treating gosling gout and preparation method thereof | |
| CN102688477A (en) | Medicinal composition for treating respiratory diseases of livestock | |
| CN102697850B (en) | Traditional Chinese medicine composition for preventing and treating pig diarrhea | |
| CN108042690B (en) | Traditional Chinese medicine composition for treating swine mycoplasmal pneumonia and application thereof | |
| CN105250825A (en) | Traditional Chinese medicine composition for treating and preventing livestock, poultry and fur-bearing animal gastroenteritis | |
| CN105994984A (en) | Traditional Chinese medicine feed additive for controlling bird flu | |
| CN106924368A (en) | Treat Chinese medicine composition of broiler chicken enteritis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20151109 Address after: 256618 No. nine, No. 480, Bohai Road, Shandong, Binzhou Applicant after: Binzhou, Shandong Province animal and veterinary research institute Address before: 256600 No. three, No. 510, the Yellow River Road, Shandong, Binzhou Applicant before: Liu Jishan |
|
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20141008 |
|
| RJ01 | Rejection of invention patent application after publication |